Enhanced immune reconstitution of γδ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.

Allogeneic stem cell transplantation (allo-SCT) is a curative treatment for several hematological malignancies including acute myeloid leukemia (AML). Considerable frequency of post-transplant relapses and non-relapse mortality (NRM) caused by Graft- versus- host diseases (GVHD), organ toxicity, and infectious complications represent limiting factors for success of this approach. Studies evaluating the impact of measurable residual disease (MRD) have been expanding in the last decades and clearly demonstrated higher relapses and lower survival in pre-transplant MRD+ AML patients.

Source: Biology of Blood and Marrow Transplantation - June 9, 2021 Category: Hematology Authors: Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Dietlinde Janson, Francis Ayuk, Christine Wolschke, Ulrike Bacher, Nicolaus Kr öger Source Type: research